Duloxetine for the long-term treatment of Major Depressive Disorder in patients aged 65 and older: An open-label study

被引：28

作者：

Wohlreich M.M. ^{[1
]}

Mallinckrodt C.H. ^{[1
]}

Watkin J.G. ^{[1
]}

Hay D.P. ^{[1
]}

机构：

[1] Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

来源：

BMC Geriatrics | / 4卷 / 1期

关键词：

Major Depressive Disorder; Major Depressive Disorder; Duloxetine; Body Mass Index; Potentially Clinically Significant;

D O I：

10.1186/1471-2318-4-11

中图分类号：

学科分类号：

摘要：

Background: Late-life depression is a common, chronic and recurring disorder for which guidelines recommend long-term therapy. The safety and efficacy of duloxetine for the treatment of major depressive disorder (MDD) were evaluated using data from elderly patients (age ≥ 65 years; n = 101) who participated in a large, multinational, open-label study. Methods: Patients meeting DSM-IV criteria for MDD received duloxetine 80 mg/d (40 mg twice daily (BID)) to 120 mg/d (60 mg BID) for up to 52 weeks. Efficacy measures included the Clinical Global Impression of Severity (CGI-S) scale, the 17-item Hamilton Rating Scale for Depression (HAMD17), the Beck Depression Inventory-II (BDI-II), the Patient Global Impression of Improvement (PGI-I) scale, and the Sheehan Disability Scale (SDS). Safety and tolerability were evaluated using discontinuation rates, spontaneously reported adverse events, and changes in vital signs, ECG, and laboratory analytes. Results: Mean changes in HAMD17 total score at Weeks 6, 28, and 52 were -13.0, -17.4 and -17.5 (all p-values <.001). Significant improvement (p < .001) in both clinician- (CGI-S) and patient-rated (PGI-I) measures of improvement were observed at Week 1 and sustained throughout the study. Observed case response rates at Weeks 6, 28, and 52 were 62.9%, 84.9%, and 89.4%, respectively, while the corresponding rates of remission were 41.4%, 69.8%, and 72.3%. Adverse events led to discontinuation in 27 (26.7%) patients. Treatment-emergent adverse events reported by >10% of patients included dizziness, nausea, constipation, somnolence, insomnia, dry mouth, and diarrhea. Most events occurred early in the study. Mean changes at endpoint in blood pressure and body weight were less than 2.0 mm Hg, and -0.1 kg, respectively. Conclusions: In this open-label study, duloxetine was effective, safe, and well tolerated in the longterm treatment of MDD in patients aged 65 and older. © 2004 Wohlreich et al; licensee BioMed Central Ltd.

引用

共 34 条

[1]

Alexopoulos G.S., Borson S., Cuthbert B.N., Devanand D.P., Mulsant B.H., Olin J.T., Oslin D.W., Assessment of late life depression, Biol Psychiatry, 52, (2002)

[2]

Mulsant B.H., Ganguli M., Epidemiology and diagnosis of depression in late life, J Clin Psychiatry, 60, SUPPL. 20, pp. 9-15, (1999)

[3]

Rovner B.W., German P.S., Brant L.J., Clark R., Burton L., Folstein M.F., Depression and mortality in nursing homes, JAMA, 265, pp. 993-996, (1991)

[4]

Beaumont G., The toxicity of antidepressants, Br J Psychiatry, 154, pp. 454-458, (1989)

[5]

Hale A.S., New antidepressants: Use in high-risk patients, J Clin Psychiatry, 54, SUPPL., pp. 61-70, (1993)

[6]

Steffens D.C., Krishnan K.R., Helms M.J., Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta- analysis, Depress Anxiety, 6, pp. 10-18, (1997)

[7]

Wong D.T., Bymaster F.P., Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?, Prog Drug Res, 58, pp. 169-222, (2002)

[8]

Detke M.J., Lu Y., Goldstein D.J., Hayes J.R., Demitrack M.A., Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial, J Clin Psychiatry, 63, pp. 308-315, (2002)

[9]

Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., Demitrack M.A., Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression, J Psychiatr Res, 36, pp. 383-390, (2002)

[10]

Goldstein D.J., Mallinckrodt C., Lu Y., Demitrack M.A., Duloxetine in the treatment of major depressive disorder: A double- blind clinical trial, J Clin Psychiatry, 63, pp. 225-231, (2002)

← 1 2 3 4 →